Time filter

Source Type

Prague, Czech Republic

The presence of cardiovascular disease, and especially coronary artery disease, in patients with type 1 diabetes mellitus impairs life expectancy. Hyperglycaemia, which increases oxidative stress, is the key pathophysiological factor. Coronary artery calcifications, the presence of cardiac autonomic neuropathy and diabetic nephropathy are significantly associated with coronary artery disease manifestations. Likewise, the hypoglycaemic episodes significantly increase the cardiovascular risk. Based on the clinical trial outcomes, there is evidence showing that good compensation of type 1 diabetes from the time of its manifestation can significantly reduce the occurrence and progression of macrovascular complications, including coronary artery disease. The correction of hypertension and dyslipidaemia is also beneficial. Source

Urbanek P.,Interni Klinika
Gastroenterologie a Hepatologie | Year: 2015

This review presents all essential information on simeprevir and its use in the therapy of chronic hepatitis C. The review is focused on the curent role of simeprevir in IFN-based regimens as well as its role in IFN-free regimens. Source

Jankovec Z.,Interni Klinika
Interni Medicina pro Praxi | Year: 2012

Treatment with an insulin pump has gradually become a routine part of care of patients with diabetes mellitus, particularly of those with type 1 diabetes. Currently, approximately 5,500-6,000 patients, primarily centred in diabetes centres, are estimated to be treated with an insulin pump in the Czech Republic. Due to frequent comorbidities, this treatment is not exclusively in the hands of diabetologists, but increasingly involves the participation of physicians in other fields as well. The article aims at presenting a brief overview of the present knowledge on treatment with an insulin pump and current indications and options of treatment. Insulin pumps have a firm place in the care of diabetes patients; however, given the economic and personal demands of this treatment, it is necessary to carefully weigh all the benefits and possible risks, including regular reappraisal of effectiveness of and indications for continuation of this treatment. Source

After 2010 the therapy of chronic HCV infection entered a completely new era - the era that is marked with the gradual introduction of the so-called directly acting antivirals into treatment schemes of this serious disease. The term directly acting antivirals (DAA) covers low-molecular substances that inhibit viral non-structural proteins - enzymes involved in the HCV replication cycle. At present, the first 2 representatives of DAA, Boceprevir and Telaprevir, have been approved for chronic HCV infection indication. The synoptic article pays the greatest attention to these 2 representatives, along with mentioning some other substances that are under later phases of clinical development and are likely to be approved in the near future. Source

Venous thromboembolism is a common serious clinical condition, in which genetic factors play an important role, too. The Objective of this review is to summarize current knowledge regarding the hereditary thrombophilias and submit their simple classification. Recommended Consensus of the Czech Societies on Thrombosis and Haemostasis, Haematology and Medical Genetics for genetic testing in specific patients' groups at venous thromboembolism high-risk situation is also presented. Source

Discover hidden collaborations